

# PROTOCOL

## Pre-eclampsia in Hospital: Early Induction or Expectant Management



ISRCTN01879376

### Sponsor:


Name: King's College London and Guy's and St Thomas' NHS Foundation Trust  
Address: Strand  
London  
WC2R 2LS  
Telephone: 020 7836 5454

### Chief Investigators

Name: Professor Andrew Shennan/Professor Lucy Chappell  
Address: Women's Health Academic Centre  
Division of Women's Health  
10<sup>th</sup> Floor North Wing  
St. Thomas' Hospital  
London  
SE1 7EH  
Telephone: 020 7188 3639  
Email: [andrew.shennan@kcl.ac.uk](mailto:andrew.shennan@kcl.ac.uk)/[lucy.chappell@kcl.ac.uk](mailto:lucy.chappell@kcl.ac.uk)

### Name and address of Statistician

Name: Louise Linsell  
Address: NPEU, Clinical Trials Unit  
University of Oxford  
Old Road Campus  
Oxford  
OX3 7LF  
Telephone: 01865 617922  
Email: [louise.linsell@npeu.ox.ac.uk](mailto:louise.linsell@npeu.ox.ac.uk)



# CONTENTS

<b>1.</b>	<b>Study Synopsis</b>	<b>6</b>
<b>2.</b>	<b>Abbreviations</b>	<b>10</b>
<b>3.</b>	<b>Background &amp; Rationale</b>	<b>12</b>
<b>4.</b>	<b>Trial Objectives, Design and Statistics</b>	<b>13</b>
4.1.	Trial Objectives	13
4.2.	Trial Design	14
4.3.	Sub-studies	15
4.4.	Sample Size	16
4.5.	Randomisation	17
4.5.1.	Analysis	17
<b>5.</b>	<b>Selection and Withdrawal of Participants</b>	<b>19</b>
5.1.	Inclusion Criteria	19
5.1.1.	Determination of gestational age	19
5.2.	Exclusion Criterion	20
5.3.	Study Periods	20
5.4.	Withdrawal of Participants	20
<b>6.</b>	<b>Assessment of Outcomes</b>	<b>20</b>
6.1.	Primary Outcomes	20
6.2.	Secondary Outcomes	21
6.3.	Time of Delivery - Adherence to Protocol	25
<b>7.</b>	<b>Assessment of Safety</b>	<b>25</b>
7.1.	Adverse Event (AE)	25
7.2.	Serious Adverse Event (SAE)	25
7.3.	Expected Serious Adverse Events	26
7.4.	Unexpected Serious Adverse Events	27
7.5.	Safety Reporting Procedures	27
7.5.1.	SAE Recording	27
7.5.2.	Unexpected SAE reporting	27
<b>8.</b>	<b>Study Governance</b>	<b>28</b>
8.1.	NHS Trust Research and Development (R&D)	28
8.2.	Study Sponsor	28
8.3.	Study Coordinating Centre	28
8.4.	Project Management Group (PMG)	29
8.5.	Co-Investigators Group	29
8.6.	Trial Steering Committee (TSC)	29

8.7.	Data Monitoring Committee (DMC)	29
8.8.	Adjudication Panel	29
8.9.	Competing Interests	30
<b>9.</b>	<b>Direct Access to Source Data and Documents</b>	<b>30</b>
<b>10.</b>	<b>Ethics and Regulatory Approvals</b>	<b>30</b>
10.1.	Declaration of Helsinki	30
10.2.	Good Clinical Practice	30
10.3.	Approvals	30
<b>11.</b>	<b>Trial Procedures</b>	<b>31</b>
11.1.	Informed Consent	31
11.2.	Data Collection	31
11.2.1	Data Collection before Post-natal Discharge	31
11.2.2	Data Collection after Discharge	32
11.3.	Data Processing	33
11.4.	Masking	33
11.5.	End of Trial	33
11.6.	Early Cessation	34
<b>12.</b>	<b>Participant Confidentiality, Data Handling and Record Keeping</b>	<b>34</b>
12.1.	Retention of Personal Data	35
12.2.	Data Security	35
12.3.	Insurance	35
<b>13.</b>	<b>Quality Control and Assurance</b>	<b>35</b>
13.1.	Site Initiation and Training	35
13.2.	Site Monitoring and Auditing	36
13.3.	Risk Assessment	36
13.4.	National Registration Systems	36
<b>14.</b>	<b>Communication</b>	<b>36</b>
14.1.	Study Website	36
14.2.	Publication Policy	36
<b>15.</b>	<b>Finance</b>	<b>37</b>
15.1.	Funding	37
<b>16.</b>	<b>Signatures</b>	<b>38</b>
16.1.	Protocol Approval Signatures	38
16.2.	Site Principal Investigator Signatures	39
<b>17.</b>	<b>References</b>	<b>40</b>

Appendix 1	PEACOCK (PHOENIX – 2) Study	43
Appendix 3	PHOEBE (PHOENIX – 3) Study	54
Appendix 3	Study Procedures for each study	66

## 1. Study Synopsis

<b>Title of Clinical Trial</b>	Pre-eclampsia in Hospital: Early Induction or Expectant Management
<b>Protocol Acronym</b>	PHOENIX
<b>Study Phase</b>	Phase III
<b>Sponsor Name</b>	King's College London
<b>Chief Investigators</b>	Professor Andrew Shennan/Professor Lucy Chappell
<b>REC number</b>	13/SC/0645
<b>Medical Condition or Disease Under Investigation</b>	Women 34 <sup>+0</sup> to 36 <sup>+6</sup> weeks of gestation with pre-eclampsia
<b>Purpose of Clinical trial</b>	To determine whether delivery in women with pre-eclampsia between 34 <sup>+0</sup> and 36 <sup>+6</sup> weeks of gestation reduces maternal complications without short and long term detriment to the infant compared to expectant management and delivery at 37 weeks of gestation.
<b>Primary Objective</b>	<p>The primary short term objective of the study is both:</p> <ul style="list-style-type: none"> <li>To determine if delivery in women with pre-eclampsia between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation reduces adverse maternal outcomes up to post-natal discharge of the mother from hospital</li> </ul> <p>And:</p> <ul style="list-style-type: none"> <li>To determine the impact of early delivery on the incidence of perinatal deaths within 7 days of delivery (excluding deaths due to congenital anomaly) or neonatal unit (NNU) admissions up to time of infant hospital discharge</li> </ul> <p>The primary long term objective is;</p> <ul style="list-style-type: none"> <li>To determine the impact of both management strategies on infant neurodevelopmental status at 2 years of age corrected for prematurity</li> </ul>
<b>Secondary Objective(s)</b>	<p>The secondary objectives of the study are:</p> <ul style="list-style-type: none"> <li>To investigate the effect of early delivery on other short term outcomes for both mother and infant</li> <li>To assess the impact of both management strategies on maternal and infant health economic outcomes</li> <li>To evaluate maternal quality of life prior to delivery then at 6 months and 2 years</li> </ul>
<b>Trial Design</b>	<p>This will be a randomised controlled trial of planned immediate delivery (up to 48 hours) after randomisation of women between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation versus expectant management and delivery at 37 weeks of gestation in women with pre-eclampsia. The main study will be preceded by a pilot study to determine whether the study design and procedures will enable the objectives and recruitment targets to be met.</p> <p>The study will be conducted at approximately 35 centres across England and Wales; 6 centres will be involved in the pilot study.</p>

<p><b>Outcomes</b></p>	<p><b>Primary outcomes:</b></p> <p><b>Primary short term maternal outcome:</b> Composite of maternal morbidity of fullPIERS outcomes with the addition of recorded systolic blood pressure <math>\geq 160</math> mmHg (with or without medication) post randomisation.</p> <p><b>Primary short term perinatal outcome:</b> Composite of perinatal deaths (antenatal/intrapartum stillbirths and deaths within 7 days of delivery but not deaths due to congenital anomalies) or NNU admissions (physical separation of baby from the mother) prior to infant hospital discharge.</p> <p><b>Primary long term infant outcome:</b> PARCA-R Parent Report Composite score for neurodevelopment at two years of age corrected for prematurity.</p> <p><b>Secondary outcomes:</b></p> <p><b>Secondary short term maternal outcomes:</b> Individual components of the composite primary outcome plus;</p> <ul style="list-style-type: none"> <li>• Use of anti-hypertensive drugs</li> <li>• Progression to severe pre-eclampsia post randomisation (defined as systolic blood pressure <math>\geq 160</math> mmHg, platelet count <math>&lt; 100 \times 10^9</math>/litre, abnormal liver enzymes (ALT or AST <math>&gt; 70</math> iu/litre))</li> <li>• Estimated fetal weight (on ultrasound scan) <math>&lt; 10^{\text{th}}</math> centile post-enrolment</li> <li>• Absent or reversed end diastolic flow (on umbilical artery Doppler)</li> <li>• Time and mode of onset (spontaneous, induced or pre-labour caesarean section) and mode of delivery (spontaneous vaginal delivery, assisted vaginal delivery, caesarean section)</li> <li>• Confirmed thromboembolic disease requiring anticoagulation up to post-natal discharge</li> <li>• Confirmed sepsis (positive blood or urine cultures) up to post-natal discharge</li> <li>• Primary and additional indications for delivery in expectant management arm (maternal hypertension not controlled by maximal therapy, biochemical abnormality, haematological abnormality, fetal compromise on ultrasound scan, fetal compromise on cardiotocography, severe maternal symptoms, 37 weeks gestation or specified other)</li> <li>• Placental abruption</li> </ul> <p><b>Secondary short term perinatal outcomes</b></p> <ul style="list-style-type: none"> <li>• Stillbirth post randomisation</li> <li>• Neonatal death prior to hospital discharge</li> <li>• Admissions to NNU</li> <li>• Number of nights in each category of care (intensive, high dependency, special, transitional and normal)</li> <li>• Total number of nights in hospital</li> <li>• Birth weight (g)</li> </ul>
------------------------	---

	<ul style="list-style-type: none"> <li>• Customised/population birth weight centile</li> <li>• Birth weight &lt;10<sup>th</sup> and &lt;3<sup>rd</sup> customised/population centile</li> <li>• Gestational age at delivery</li> <li>• APGAR score at 5 minutes post birth</li> <li>• Umbilical arterial and venous pH (and base excess) at birth</li> <li>• Need for supplementary oxygen prior to discharge</li> <li>• Number of days when supplemental oxygen is required</li> <li>• Need for ventilation support (CPAP/high flow/endotracheal ventilation)</li> <li>• Pneumothorax (confirmed on chest X-ray)</li> <li>• Abnormal cerebral ultrasound scan</li> <li>• Confirmed sepsis (positive blood or cerebrospinal fluid cultures)</li> <li>• Necrotising enterocolitis (Bell's stage II and III)</li> <li>• Seizures (confirmed by EEG or requiring anticonvulsant therapy)</li> <li>• Encephalopathy grade (worst at any time: mild, moderate, severe)</li> <li>• Hypoglycaemia (blood glucose &lt;2.6 mmol/l on two or more occasions)</li> <li>• Other indications and main diagnoses resulting in NNU admission</li> <li>• Exclusively breast-fed at discharge from the neonatal unit</li> </ul> <p><b>Secondary long term maternal outcomes</b> Quality of maternal physical and mental health using the validated SF-12v2® questionnaire when the infant is 6 months and 2 years of age corrected for prematurity.</p> <p><b>Health economic/quality of life outcomes</b></p> <ul style="list-style-type: none"> <li>• Quality of life using the validated quality of life questionnaire EQ-5D-5L immediately after randomisation, at 6 months and when the infant is 2 years of age corrected age for prematurity.</li> <li>• Hospital attendances, nights and diagnostic tests from randomisation until delivery</li> <li>• Cost of delivery</li> <li>• Cost of neonatal care (hospital admissions, surgery and diagnostic tests)</li> <li>• Retrospective 6 month health/social care use by mother and infant at 6 months and 2 years</li> <li>• EQ-5D-5L for the calculation of maternal quality adjusted life years (QALYs)</li> </ul>
<b>Sample Size</b>	900 women with pre-eclampsia between 34 <sup>+0</sup> and 36 <sup>+6</sup> weeks of gestation.
<b>Summary of eligibility criteria</b>	<p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• Pregnant women between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation inclusive</li> <li>• Pre-eclampsia (as defined by International Society for the Study of Hypertension in Pregnancy {ISSHP} 2014 statement)</li> <li>• Singleton or dichorionic diamniotic (DCDA) twin pregnancy</li> <li>• Viable fetus</li> <li>• Aged 18 years or over at time of screening</li> <li>• Able to give written informed consent</li> </ul> <p><b>Exclusion criterion:</b></p>

	<ul style="list-style-type: none"> <li>Women for whom a decision has already been made to deliver within the next 48 hours</li> </ul>
<b>Interventions</b>	Planned immediate delivery (typically by induction with prostaglandins, or by Caesarean section if induction contra-indicated) undertaken as soon as feasible (up to 48 hours) after randomisation. Use of steroids will be at the discretion of the clinician. If induction fails, subsequent management options including re-induction and caesarean section should be considered. Treatment and care should take into account a woman's needs and preferences.
<b>Version and date of current protocol</b>	Version 3, dated 21 March 2016
<b>Version and date of protocol amendments</b>	Version 1, dated 11 October 2013 – Original approved version Version 2, dated 16 September 2014 Version 3, dated 21 March 2016

## 2. Abbreviations

<b>ACOG</b>	American College of Obstetricians and Gynaecologists
<b>AE</b>	Adverse Event
<b>APEC</b>	Action on Pre-eclampsia
<b>ARR</b>	Absolute Risk Reduction
<b>BP</b>	Blood Pressure
<b>CI</b>	Chief Investigator
<b>CIG</b>	Co-Investigator Group
<b>CSF</b>	Cerebrospinal Fluid
<b>CTRG</b>	Clinical Trials and Research Governance, University of Oxford
<b>DMC</b>	Data Monitoring Committee
<b>eCRF</b>	Electronic Case Report Form
<b>FTE</b>	Full Time Equivalent
<b>GCP</b>	Good Clinical Practice
<b>GP</b>	General Practitioner
<b>HELLP</b>	Hemolysis, Elevated Liver enzymes and Low Platelet count
<b>HTA</b>	Health Technology Assessment
<b>ICER</b>	Incremental Cost-Effectiveness Ratio
<b>ICF</b>	Informed Consent Form
<b>IRAS</b>	Integrated Research Application System
<b>ISF</b>	Investigator Site File
<b>ISSHP</b>	International Society for the Study of Hypertension in Pregnancy
<b>LRMN</b>	Local Research Midwife or Nurse
<b>NEC</b>	Necrotising Enterocolitis
<b>NHSIC</b>	National Health Service Information Centre
<b>NUU</b>	Neonatal Unit
<b>NICE</b>	National Institute for Health and Clinical Excellence
<b>NIHR</b>	National Institute for Health Research
<b>NPEU CTU</b>	National Perinatal Epidemiology Unit Clinical Trials Unit
<b>NRES</b>	National Research Ethics Service
<b>ONS</b>	Office for National Statistics
<b>PARCA-R</b>	Parent Report of Cognitive Abilities-Revised
<b>PI</b>	Principal Investigator
<b>PIL</b>	Participant Information Leaflet
<b>PMA</b>	Post-menstrual Age
<b>PMG</b>	Project Management Group

<b>PRC</b>	Parent Report Composite
<b>PROM</b>	Patient Reported Outcome Measures (questionnaire)
<b>PSS</b>	Personal Social Services
<b>QALY</b>	Quality Adjusted Life Years
<b>R&amp;D</b>	NHS Trust Research and Development
<b>REC</b>	Research Ethics Committee
<b>RR</b>	Risk Ratio
<b>SAE</b>	Serious Adverse Event
<b>SBP</b>	Systolic Blood Pressure
<b>SOP</b>	Standard Operating Procedure
<b>SVD</b>	Spontaneous Vaginal Delivery
<b>TRM</b>	Trial Research Midwife
<b>TMF</b>	Trial Master File
<b>TSC</b>	Trial Steering Committee

### 3. Background & Rationale

In the UK, 10-15% of pregnant women develop hypertension in pregnancy, and 2-8% pre-eclampsia. Pre-eclampsia is a multisystem disorder, characterised by placental and maternal vascular dysfunction which is associated with significant morbidity and mortality for the mother and infant. Adverse outcomes of pre-eclampsia include severe hypertension, stroke, renal and hepatic injury, haemorrhage, fetal growth restriction and even death<sup>1</sup>.

Early delivery may be indicated to prevent maternal and infant morbidity. Standard management of pre-eclampsia involves close monitoring whilst taking into consideration the gestational age of the fetus, fetal well-being and rate of progression of maternal disease to instigate timely delivery if needed. When a diagnosis of pre-eclampsia is made at or beyond 37 weeks of gestation, it is currently recommended that delivery be induced, since maternal and fetal risks can be significantly reduced without any apparent added risk associated with the intervention.

Nearly half (40%) of all pre-eclampsia occurs preterm (before 37 weeks), and these cases will have the most serious outcomes. Using data from previous pre-eclampsia trials<sup>2, 3</sup>, we have estimated that 33% of women with pre-eclampsia will present between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation and not require immediate delivery.

Delivery before 34 weeks (meta-analysis of two randomised controlled trials, n=133)<sup>4</sup> demonstrates worse neonatal risk (Hyaline Membrane Disease risk ratio (RR) 2.3 (95% CI 1.39 to 3.81) and necrotising enterocolitis (NEC) RR 5.54 (95% CI 1.04 to 29.56)) without sufficient benefit in maternal outcomes.

The optimal time to instigate delivery to prevent morbidity when pre-eclampsia occurs between 34 and 37 weeks of gestation, without increasing problems related to infant immaturity or complications, remains unclear. Current management involves close surveillance and action only when evidence of impending serious morbidity becomes apparent (e.g. deteriorating maternal or fetal conditions). As this may be rapid or unexpected, routine delivery beyond 34 weeks may be valuable. Neonatal and infant mortality and morbidity may, nonetheless, be significant following delivery between 34 and 37 weeks of gestation. Respiratory function may be adversely affected, leading to hypoxic insult and as a result possible brain damage and chronic lung disease; however, this may be related to the underlying pathology that precipitated delivery i.e. placental insufficiency and hypoxia. However, neurodevelopmental morbidity and risk of growth restriction and death may be reduced by early delivery, lowering the risk of behavioural problems and intellectual impairment in later life, and adverse events related to expectant management (including stillbirth and worsening growth restriction) may be decreased.

It is highly likely that routine delivery will reduce the maternal risk, as delivery cures pre-eclampsia. There is therefore a need to compare a policy of planned delivery between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation with that of expectant management, with particular regard to the benefit to the mother, whilst ensuring no increased risk to the baby, particularly in relation to longer neurodevelopmental outcomes.

This aim of this study is to remove the uncertainty about the timing of delivery in pregnancies affected by pre-eclampsia between 34 and 37 weeks of gestation. The study will be conducted according to the principles of the Declaration of Helsinki (dated 2008) and all applicable regulatory requirements. This protocol will be submitted to a NHS Research Ethics Committee (REC) and NHS Trust Research and Development Offices for approval.

## 4. Trial Objectives, Design and Statistics

### 4.1. Trial Objectives

The aim of this study is to determine whether planned delivery in women with pre-eclampsia between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation reduces maternal adverse outcomes without substantial worsening of neonatal/infant outcomes, compared with the current practice of expectant management and delivery at 37 weeks of gestation.

The primary objectives of the study are:

- To determine if planned early delivery for women with pre-eclampsia between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation reduces adverse maternal outcomes based on a composite listed in the fullPIERS<sup>5</sup> paper with addition of recorded systolic hypertension (systolic blood pressure (SBP) of  $\geq 160$  mmHg), as highlighted in the triennial Confidential Enquiry into Maternal Deaths (2006-8)<sup>9</sup>.
- To evaluate the impact of the intervention on short and long term neonatal outcomes. Short term outcomes will be as assessed by a composite of perinatal deaths (antenatal/intrapartum stillbirths plus neonatal deaths within 7 days, but not deaths due to congenital anomaly) and neonatal unit (NNU) admissions up to time of infant hospital discharge.
- To determine the impact of both management strategies on infant neurodevelopmental status at two years of age corrected for prematurity using PARCA-R<sup>6</sup> Parent Report Composite.

The secondary objectives of the study are:

- To investigate the effect of intervention on other secondary maternal and neonatal short term outcomes.
- To assess the impact of both management strategies on health care resource use and quality adjusted life years (QALYs); in terms of the total number of nights for mother and neonate, including intensive care use from randomisation until delivery, health care resource use for mother and infant retrospectively at 6 months and 2 years post-delivery covering the previous 6 months; EQ-5D-5L<sup>7</sup> for the mother at baseline, 6 months and 2 years corrected age.
- To assess the impact of both management strategies on health economic outcomes: for mother and infant in terms of number of nights in each hospital setting, cost data to post-natal hospital discharge, health/social care use (using client Socio-Demographic and Service Receipt Inventory) at 6 months and 2 years corrected age post-delivery.
- To evaluate quality of life using questionnaires immediately after randomisation and at 6 months and 2 years corrected age.

#### 4.2. Trial Design

This will be a pragmatic, multicentre, randomised controlled trial of planned delivery versus expectant management in 900 women with pre-eclampsia between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation inclusive.

The trial will be conducted in approximately 35 consultant-led maternity units across England and Wales. A pilot phase will initially be run, involving 6 centres over a period of six months to establish whether the procedures and assessments are conducive to achieving the recruitment and other objectives of the study.

Recruitment is anticipated to take 36 months based on an assumption that each centre will on average recruit 1.5 women per month, with some allowance for unforeseen events and centres recruiting slower than expected. The study, including set-up, pilot phase, completion of mother and infant follow-up and reporting, is anticipated to take 72 months to complete.

Both the maternal and neonatal short term outcomes will be determined quickly as the time period from randomisation to outcome collection will not exceed 8 weeks (delivery + 28 days post-birth) and in many cases will be less. If the processes are shown to work in the pilot phase, recruitment to the main trial will proceed with no break and data from the pilot phase will be analysed together with the main trial data collected.

An economic evaluation from the perspective of the National Health Service (NHS) and Personal Social Services (PSS) will be conducted alongside the main trial. Data on health and social care resource utilisation will be collected using patient administration systems, maternity and neonatal databases and logs of tests and procedures, together with data from questionnaires administered at 6 months and 2 years, capturing health and social care resource use for mother and child in the previous 6 months. No information on health or social care resource use will be collected from 6 to 18 months to reduce responder burden. Health and social care services will be costed using national published sources (NHS reference costs, Unit Costs of Health and Social Care (Personal Social Services Research Unit, British National Formulary)). Quality adjusted life years (QALYs) for the mother will be calculated from EQ-5D-5L<sup>7</sup> utility scores collected at baseline, 6 months and 2 years and the SF-12v2<sup>®8</sup> questionnaire also at 6 months and 2 years. These will be calculated as the area under the curve, adjusting for baseline differences using regression analysis. Differences in infant mortality between the two groups will be captured by assuming full health up to 2 years for surviving infants. A sensitivity analysis will be conducted where infant utility scores will be adjusted for any health or developmental problems observed over the 2 years. Where possible these values will be obtained from the literature. The final results of the economic evaluation analyses will be expressed as the mean incremental cost per mean QALY gained from baseline until 2 years follow up. Cost and QALYs in the second year will be discounted in line with NICE guidance<sup>10</sup>. Confidence intervals for costs and QALYs will be calculated using bootstrapping, the results of which will be used to construct cost-effectiveness planes and interpreted using cost-effectiveness curves. One, two and multi-way sensitivity analyses will be conducted for any assumptions made.

#### **4.3. Sub-studies**

Two nested studies will run alongside the PHOENIX study, at selected recruitment centres. The nested studies are to be included within the main PHOENIX study's regulatory approval and will only start once they have received approval from the REC. Additionally, approval of the appropriate Trust R&D Office will be sought for all study sites conducting these nested studies.

All women identified as eligible for the main PHOENIX study are eligible to participate in both the PEACOCK (PHOENIX-2) and PHOEBE (PHOENIX-3) nested studies, whether they agree or decline randomisation into the main PHOENIX study. Eligible women will be given a separate patient information leaflet and asked to sign a separate consent forms for each of these nested studies.

A detailed description of each study is included within Appendixes 1 and 2 of this protocol.

#### 4.4. Sample Size

The sample size for the PHOENIX study is calculated on the ability to observe a clinically significant risk reduction in the primary short term maternal composite outcome of maternal morbidity and recorded systolic blood pressure of  $\geq 160$  mmHg, measured after randomisation.

##### **Superiority hypothesis in maternal outcome**

Based on data from the PELICAN study<sup>2</sup>, 49 of 115 women with suspected pre-eclampsia (42.6%, 95% CI 33.4% to 52.2%) enrolled between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation developed maternal morbidity and hypertension of  $\geq 160$  mmHg. Therefore, assuming an expected adverse maternal outcome incidence of 43% in the control group (expectant management), a sample size of 850 women will be needed to demonstrate a relative risk reduction of 25% to 32.25% (deemed clinically significant) with a 2-sided 5% significance level in the planned delivery group. Taking into account a 5% loss of women in follow-up, the overall target sample size for the study is 900 women (450 per group).

##### **Non-inferiority hypothesis in neonatal outcome**

A sample size of 850 women will result in approximately 860 live births (assuming 1 in 80 pregnancies are twin pregnancies). The PELICAN study<sup>2</sup> reported that a composite of perinatal death or any neonatal admission occurred in 27 of 115 infants (23.5%, 95% CI 16.1% to 32.3%). Assuming a composite adverse neonatal outcome incidence of 24% in the control group (expectant management), a sample size of 860 (430 per group) will achieve 93% power to detect a non-inferiority margin of difference in incidence of no less than 10% and 78% power to detect a margin of no less than 8%.

In order to examine the component of perinatal death specifically, using Office for National Statistics (ONS) data for all babies born in England and Wales in 2013<sup>11</sup>, of all pre-term births, 1.6% (585/36939) were perinatal deaths (stillbirth and early neonatal). A similar incidence is expected in women with pre-eclampsia as those deaths prevented by increased surveillance would be offset by pre-eclampsia associated co-morbidities of fetal growth restriction and placenta abruption. Thus, for the component of perinatal death, assuming a control group incidence of 1.5%, a sample size of 430 in each group would achieve 90% power to detect a non-inferiority margin of difference in incidence of no less than 2.7%. A non-inferiority margin of difference in incidence of no less than 2.3% would be detected with 79% power. If the control group incidence was 1%, then a margin of no less than 2.2% could be detected with 90% power, and 1.9% with 80% power.

For the component of neonatal unit admission, assuming a control group incidence of 21%, a sample size of 430 in each group will achieve 90% power to detect a non-inferiority margin of difference in incidence of no less than 9%. A non-inferiority margin of difference in incidence of no less than 8% would be detected with 82% power.

Assuming a loss to follow-up at two years of 20% we should obtain long term outcomes for approximately 690 infants (345 per group assuming no difference in the loss to follow-up between the groups). The PARCA-R<sup>6</sup> questionnaire provides a composite score for neurodevelopment with a standardised mean of 100 and standard deviation of 15. With a one-sided significance level of 2.5%, under a non-inferiority hypothesis, a sample size of 345 in each group achieves a 94% power to detect a non-inferiority margin of difference in the mean PARCA-R score of no less than 4 points (1/4 of a standard deviation). A margin of no less than 3 points can be detected with 75% power.

#### **4.5. Randomisation**

The allocation ratio of intervention (planned delivery) to control (expectant management) will be 1:1. Randomisation will be managed via a secure web-based randomisation facility hosted by MedSciNet with telephone back-up available at all times. A minimisation algorithm will be used to ensure balance between the groups with respect to the collaborating hospital, singleton/twin pregnancies, severity of hypertension in 48 hours prior to enrolment (highest systolic blood pressure with or without medication:  $\leq 149$  mmHg, 150-159 mmHg,  $\geq 160$  mmHg), parity, previous caesarean section and gestational age at randomisation (34/35/36 weeks). MedSciNet will write the randomisation program and hold the allocation code.

Following randomisation, the consultant obstetrician will then arrange for delivery or ongoing expectant management as the randomisation indicates.

##### **4.5.1. Analysis**

The primary analysis for all maternal outcomes will be by intention to treat with participants analysed in the groups to which they are assigned regardless of deviation from the protocol or intervention received.

The primary analysis for all perinatal and infant outcomes will be both an intention to treat and a per-protocol analysis, since the hypothesis under examination for these outcomes is a non-inferiority hypothesis. The per-protocol analysis will exclude babies of women who do not receive the allocated intervention as per protocol and will be further defined in the Statistical Analysis Plan. Evidence suggesting non-inferiority will be concluded if results using both populations are consistent with each other. If women in the expectant management arm are delivered prior to 37 weeks of gestation due to clinical need (i.e. with new indications for delivery by NICE guidelines<sup>12,13</sup>) this will not be considered a protocol deviation.

All outcomes will be analysed adjusting for minimisation factors at randomisation<sup>14</sup> where possible. Binary outcomes will be analysed using log binomial regression models. Results will be presented as adjusted risk ratios with associated confidence intervals. If the model does not converge, log Poisson regression models with robust variance estimation will be used<sup>15</sup>. Continuous outcomes will be analysed using linear regression models. Results will be presented as adjusted differences in means and associated confidence intervals. 95% confidence intervals will be presented for all primary and secondary outcomes.

For the analysis of perinatal outcomes the adjusted analysis will also account for the correlation of outcomes in twins included in the trial by adjusting standard errors for clustering by mother. Pre-specified sub-group analysis will be undertaken on all three co-primary outcomes for parity, mild versus all other degrees of hypertension, gestation at the time of randomisation and for singleton versus twin pregnancy. The consistency of the effect of planned delivery versus expected management across subgroups will be assessed using the standard statistical test of interaction. Results will be presented as adjusted risk ratios with confidence intervals. A sensitivity analysis will be conducted on the maternal co-primary outcome excluding women who do not receive the allocated intervention as per protocol.

Lost to short term follow-up is expected to be about 5%. A sensitivity analysis will be conducted on the short term co-primary outcomes using multiple imputation methods to impute missing data, assuming that the outcome is not linked to the reason for being lost to follow-up (i.e. missing at random).

Loss to long term follow-up is expected to be around 20%. Babies for whom no 2 year follow-up data are received will be compared to babies with 2 year data on demographic and clinical characteristics as well as short term outcomes. Severity of disability is expected to be linked to loss to long term follow-up and so imputation techniques will not provide meaningful information. For partially complete data collection forms received, a sensitivity analysis will be performed using multiple imputation methods to impute missing data under the assumption that the data are missing at random, where more than 5% of an outcome is missing.

Each centre will be asked to maintain a screening log of all women presenting with pre-eclampsia, that will collect their basic demographic data together with their eligibility to allow an assessment of generalisability.

## 5. Selection and Withdrawal of Participants

### 5.1. Inclusion Criteria

Women who meet the following criteria will be eligible for enrolment into the study;

- Pregnancy of between 34<sup>+0</sup> and 36<sup>+6</sup> weeks of gestation inclusive (see section 5.1.1 for determination of gestational age)

- Pre-eclampsia

For the purposes of this study; pre-eclampsia is defined by the ISSHP 2014<sup>16</sup> statement as meeting the following criteria after 20 weeks gestation:

diastolic blood pressure (BP)  $\geq 90$  mmHg (twice,  $\geq 4$  hours and  $< 1$  week apart) (or diastolic

BP

$\geq 110$  mmHg on one occasion (ACOG<sup>17</sup> criterion))

- and one or more of the following:

- Proteinuria ( $\geq 0.3$  g/day by 24-hour urine collection, or  $\geq 30$  mg/mmol by spot urinary protein creatinine ratio)
- Thrombocytopenia (platelet count  $< 150 \times 10^9/L$ )
- Renal insufficiency (creatinine  $\geq 90$   $\mu\text{mol/L}$ )
- Impaired liver function (ALT or AST  $> 70$  IU/L)
- Fetal growth restriction (EFW  $< 10$ th centile confirmed by ultrasound)

**Or Superimposed pre-eclampsia**

- Singleton or dichorionic diamniotic twin pregnancy
- Viable fetus
- Aged 18 years or over at the time of screening
- Able to give written informed consent

Women with any other co-morbidity (including pre-existing hypertension, diabetes etc.) or having had a previous caesarean section or with the fetus in any position will be eligible.

#### 5.1.1. Determination of gestational age

For all calculations relating to gestational age (eligibility for enrolment, gestational age at delivery), gestational age will be calculated based on the following hierarchical model, as set out in the NICE guidelines for antenatal care:

- i) From crown-rump length measurement on early ultrasound scan between 10<sup>+0</sup> weeks and 13<sup>+6</sup> weeks
- ii) From head circumference on ultrasound scan if crown-rump length is above 84 mm

## **5.2. Exclusion Criterion**

Women will be excluded from participation in the study if;

- A decision has already been made to deliver within the next 48 hours

## **5.3. Study Periods**

A woman's participation in the study may be from 34 weeks of gestation until their child reaches two years of age corrected for prematurity; thus a maximum duration of 28 months.

## **5.4. Withdrawal of Participants**

Women will be able to withdraw their consent at any time without giving a reason. Withdrawal from the study will not affect their (or their baby's) on-going care and there will be no requirement for any study related follow-up safety assessments. Women may also be withdrawn from the study if their clinician feels it is in their baby's best interests.

If a participant chooses to withdraw from receiving the allocated intervention, they will be asked for permission for us to use the study data already collected and to complete data collection and/or follow-up.

For a woman allocated to the expectant management group, the attending clinician will make a decision for delivery based on the NICE guidelines, with delivery planned for 37 weeks of gestation. If clinical needs dictate delivery prior to 37 weeks gestation, this will not constitute withdrawal from the trial allocation.

For a woman allocated to the planned delivery group, if the woman should decide that she does not wish to proceed with the planned delivery, and instead chooses to continue to be monitored by her attending clinician, this will not constitute withdrawal from the study. An Incident Report Form will be required to record her decision but she should remain in the study unless she specifically requests to be withdrawn.

There is no requirement to replace women who do not complete the study or need to be delivered prior to their planned delivery date.

# **6. Assessment of Outcomes**

## **6.1. Primary Outcomes**

Primary short-term maternal outcome:

- Composite of maternal morbidity of fullPIERS outcomes (see the PHOENIX trial handbook) with the addition of recorded systolic blood pressure  $\geq 160$  mmHg (with or without medication) post randomisation.

Primary short-term perinatal outcome

- Composite of perinatal deaths (antenatal/intrapartum stillbirths and deaths within 7 days of delivery but not deaths due to congenital anomalies) or NNU admissions (physical separation of baby from the mother) prior to infant hospital discharge.

Primary long-term infant outcome

- PARCA-R Parent Report Composite score for neurodevelopment at two years of age corrected for prematurity.

## 6.2. Secondary Outcomes

Secondary **maternal** outcomes will include assessment of:

- Severe hypertension post randomisation (systolic BP  $\geq 160$  mmHg with or without medication on at least one occasion)
- Use of anti-hypertensive drugs
- Progression to severe pre-eclampsia (defined as systolic blood pressure  $\geq 160$  mmHg, platelet count  $< 100 \times 10^9$ /litre, abnormal liver function enzymes (ALT or AST  $> 70$  iu/litre))
- Estimated fetal weight (on ultrasound scan)  $< 10^{\text{th}}$  centile post-enrolment
- Absent or reversed end diastolic flow (on umbilical artery Doppler)
- Time and mode of onset (spontaneous, induced or pre-labour caesarean section) and mode of delivery (spontaneous vaginal delivery, assisted vaginal delivery, caesarean section)
- Confirmed thromboembolic disease requiring anticoagulation up to post-natal discharge
- Confirmed sepsis (positive blood or urine cultures) up to post-natal discharge
- Primary and additional indications for delivery in the expectant management arm (maternal hypertension not controlled by maximal therapy, biochemical abnormality, haematological abnormality, fetal compromise on ultrasound scan, fetal compromise on cardiotocography, severe maternal symptoms, 37 weeks of gestation or specified other)
- Placental abruption

Secondary **perinatal** outcomes will include assessment of:

- Stillbirth post randomisation
- Neonatal death prior to hospital discharge

- Admissions to NNU
- Number of nights in each category of care (intensive, high dependency, special, transitional and normal)
- Total number of nights in hospital
- Birth weight (g)
- Customised/population birth weight centile
- Birth weight <10<sup>th</sup> and <3<sup>rd</sup> customised/population centile
- Gestational age at delivery
- APGAR score at 5 minutes post birth
- Umbilical arterial and venous pH (and base excess) at birth
- Need for supplementary oxygen prior to discharge
- Number of days when supplemental oxygen is required
- Need for ventilation support (CPAP/high flow/endotracheal ventilation)
- Abnormal cerebral ultrasound scan
- Confirmed sepsis (positive blood or CSF cultures)
- Necrotising enterocolitis (Bell's stage 2 and 3)
- Seizures (confirmed by EEG or requiring anticonvulsant therapy)
- Encephalopathy grade (worst at any time: mild, moderate, severe)
- Hypoglycaemia (blood glucose <2.6 mmol/l on two or more occasions)
- Other indications and main diagnoses resulting in NNU admission
- Exclusively breast-fed at discharge from the neonatal unit

Secondary **long term maternal** outcomes will include assessment of:

- Quality of maternal physical and mental health using the validated SF-12v2® questionnaire when the infant is 6 months and 2 years of age corrected for prematurity.

Secondary **health economic and quality of life** outcomes will include assessment of:

- Quality of life using the validated quality of life questionnaire EQ-5D-5L<sup>7</sup> immediately after randomisation, at 6 months and when the infant is 2 years of age corrected for prematurity
- Hospital attendances, nights and diagnostic tests from randomisation until delivery
- Cost of delivery
- Cost of neonatal care (hospital admissions, surgery and diagnostic tests)
- Retrospective 6 month health/social care use by mother and infant at 6 months and 2 years

EQ-5D-5L<sup>7</sup> for the calculation of maternal quality adjusted life years (QALYs)

## Study Procedures (for Assessing Outcomes)

Procedure	Screening <sup>1</sup>	Randomisation	Delivery <sup>2</sup>	Post-natal Hospital Discharge	6 Months Following Birth	Infant 2 Years of Age Corrected for Prematurity
Obstetric Medical History	✓					
Consent	✓					
Demography	✓					
Blood Pressure	✓ <sup>3</sup>	✓ <sup>4</sup>	✓ <sup>5</sup>	✓ <sup>6</sup>		
Haematology and Biochemistry	✓ <sup>7</sup>	✓ <sup>8</sup>		✓ <sup>9</sup>		
Reason for Delivery			✓			
Mode of Delivery			✓			
Birth weight			✓			
Umbilical Venous and Arterial pH			✓			
APGAR Assessment			✓			
SAEs <sup>10</sup>		✓	✓	✓		
Concomitant Medication <sup>11</sup>	✓	✓	✓	✓		
PARCA-R Assessment						✓
EQ-5D-5L <sup>12</sup> Questionnaire		✓			✓	✓
SF-12 v2® Questionnaire					✓	✓

<sup>1</sup> Screening to be conducted of all women suspected of being eligible for the study.

<sup>2</sup> Delivery to be commenced within 48 hours of randomisation for women randomised to the planned delivery group.

<sup>3</sup> Eligibility for study to be assessed from blood pressure recorded at the time the diagnosis of pre-eclampsia

<sup>4</sup> Blood systolic pressure reading within the 48 hours prior to randomisation to be recorded.

<sup>5</sup> Highest systolic blood pressure recorded between randomisation and delivery to be recorded.

<sup>6</sup> Highest systolic blood pressure recorded between delivery and discharge to be recorded.

<sup>7</sup> Haematology and/or Biochemistry results that contributed to diagnosis of pre-eclampsia to be recorded.

<sup>8</sup> The most recent Haematology and/or Biochemistry results prior to randomisation to be recorded.

<sup>9</sup> Abnormal Haematology and/or Biochemistry results from randomisation to discharge to be recorded at discharge

<sup>10</sup> Serious Adverse Events (SAEs) to be recorded from randomisation to post-natal discharge. Only unexpected SAEs to be reported.

<sup>11</sup> Brief details of anti-hypertensive and medication for induction will be recorded; all other concomitant medication will only be recorded in the event that an unexpected SAE is reported.

<sup>12</sup> EQ-5D-5L<sup>7</sup> to be given to the participant to complete immediately after randomisation.

The management of pregnant women whilst in hospital should be in accordance with the NICE guidelines for the Management of Hypertension in Pregnancy<sup>12,13</sup>. Delivery will be in accordance with standard procedures but will most likely be through induction with prostaglandins, unless contraindicated. If induction fails, other management options including caesarean section should be considered. All options should be discussed with the pregnant woman and her needs and preferences taken into account.

Otherwise, women will be managed as follows:

### **Intervention (Planned Delivery) Group**

Planned delivery with minimal delay (with initiation of delivery within 48 hours of randomisation to allow for steroid use and neonatal cot availability). Use of corticosteroids will be left to the discretion of the individual clinician as indicated in the NICE guidelines. Postnatal care should follow NICE guidelines<sup>12,13</sup>.

### **Control (Expectant Management) Group**

Expectant management of pregnancy, as indicated by the NICE guidelines and delivery at 37 weeks of gestation or sooner as clinical needs dictate.

The NICE guidelines cover care on admission to hospital, treatment, measurement of blood pressure, testing for proteinuria and other parameters depending whether the woman has mild or moderate hypertension.

If **mild** hypertension (blood pressure 140/90 to 149/99 mmHg) care would be as follows;

- Admission to hospital
- Measure BP at least 4x a day
- No treatment of blood pressure
- No repeat quantification of proteinuria
- Blood test monitoring twice a week to determine kidney function, electrolytes, full blood count, transaminases, bilirubin.

If **moderate** hypertension (blood pressure 150/100 to 159/109 mmHg) care would be as for mild hypertension with the addition of the following assessments:

- Administration of oral labetalol to keep diastolic blood pressure between 80-100 mmHg/systolic blood pressure < 150 mmHg)
- Blood test monitoring thrice a week to determine kidney function, electrolytes, full blood count, transaminases, bilirubin.

### **6.3. Time of Delivery - Adherence to Protocol**

Following randomisation to either the planned delivery group or expectant management group, the time of the onset of planned delivery (first method for induction of labour or time of planned caesarean section along with the indication) or onset of spontaneous labour will be recorded for all women. This will enable the monitoring of adherence to the protocol for both study groups to be reviewed and protocol deviations to be identified and investigated.

## **7. Assessment of Safety**

A Data Monitoring Committee (DMC) will be established to ensure the wellbeing of study participants. The DMC will periodically review study progress and outcomes as well as reports of unexpected SAEs. The DMC will, if appropriate, make recommendations regarding continuance of the study or modification of the study protocol.

### **7.1. Adverse Event (AE)**

An adverse event is any untoward medical occurrence in a participant, which does not necessarily have to have a causal relationship with this intervention. Due to the high incidence of adverse events routinely expected in this patient population (e.g. abnormal laboratory findings, new symptoms etc.), only those adverse events identified as serious will be recorded for the trial.

### **7.2. Serious Adverse Event (SAE)**

A serious adverse event is any untoward medical occurrence that:

- Results in death
- Is life-threatening
- Requires participant hospitalisation or prolongation of existing hospitalisation
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
- Is an important medical event

The term 'severe' is often used to describe the intensity (severity) of a specific event; the event itself, however, may be of relatively minor medical significance. This is not the same as 'serious', which is based on participant/event outcome or action criteria usually associated with events that pose a threat to a participant's life or functioning.

The term 'life-threatening' in the definition of serious refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.

Medical and scientific judgement should be exercised in deciding whether an adverse event is serious in other situations.

### **7.3. Expected Serious Adverse Events**

Expected SAEs are those events which are expected in the patient population or as a result of the routine care/treatment of a patient.

The following events are expected in women with pre-eclampsia and their infants and as such do not require reporting as SAEs;

#### **Expected maternal SAEs**

- Hepatic dysfunction
- Hepatic haematoma or rupture
- Coma/impaired consciousness (Glasgow coma score <13)
- Cortical blindness
- Reversible ischaemic neurological deficit
- Retinal detachment
- Acute renal insufficiency or failure
- Postpartum haemorrhage requiring transfusion or hysterectomy
- Platelet count <50,000
- Severe uncontrolled hypertension
- Myocardial ischaemia/infarction
- Severe breathing difficulty
- Pulmonary oedema
- Sepsis
- Admission to hospital for pre-eclampsia (if managed as out-patient)

Although it is known that maternal death and strokes can occur in women with pre-eclampsia, they should still be reported as an SAE.

#### **Expected infant SAEs**

- Perinatal death (unless unexpected in this population)
- Congenital anomaly
- Low birth weight
- Reversed end diastolic flow
- Requirement for supplemental oxygen or ventilation support
- Intraventricular haemorrhage
- Sepsis confirmed by positive cerebrospinal fluid or blood cultures
- Necrotising enterocolitis

- Seizures
- Encephalopathy
- Hypoglycaemia

Although it is known that neonatal death and stillbirth can occur in infants born to women with pre-eclampsia, they should still be reported as an SAE.

#### **7.4. Unexpected Serious Adverse Events**

An unexpected SAE is any event that meets the definition of a SAE and is not detailed in the list above as expected. The following unexpected SAEs must be reported:

- Maternal death
- Maternal stroke
- Stillbirth
- Neonatal death

#### **7.5. Safety Reporting Procedures**

##### **7.5.1. SAE Recording**

All SAEs (described above) will be recorded from randomisation to post-natal discharge from hospital of mother and baby.

##### **7.5.2. Unexpected SAE reporting**

Only unexpected SAEs will be reported; these will be followed-up until post-natal discharge of mother and baby from acute hospital care.

Unexpected SAEs for both the mother and infant will be recorded and reported to the NPEU Clinical Trials Unit (CTU) within 24 hours of research staff at the site becoming aware of the event. Details of the SAE should be recorded on an SAE form (either electronically via the study database or in paper format using as filed in the Investigator Site File) paper forms should be faxed or emailed back to the NPEU CTU. If this is not possible at the time, the SAE may be reported by telephone an SAE form (electronic or paper format) should however be completed as soon as possible by the site and sent to the NPEU CTU. Follow-up SAE information should be reported on a new SAE form and this forwarded to the NPEU CTU electronically or by fax or email.

An SAE occurring to a participant will be reported to the REC that gave a favourable opinion of the study where in the opinion of the Chief Investigator the event was 'related' (resulted from

administration of any of the research procedures) and 'unexpected' in relation to those procedures. Reports of related and unexpected SAEs will be submitted within 15 working days of the Chief Investigator becoming aware of the event, using the HRA report of serious adverse event form.

All reported SAEs will be reviewed by the DMC at regular intervals throughout the study. The Chief Investigators will inform all Investigators concerned of relevant information that could adversely affect the safety of participants.

## **8. Study Governance**

### **8.1. NHS Trust Research and Development (R&D)**

Individual sites will only start recruitment once they have received approval from their NHS Trust Research and Development (R&D) Office. Applications to R&D offices will be submitted through the NIHR approval system.

### **8.2. Study Sponsor**

The study is co-sponsored by Kings College London and Guy's and St Thomas' NHS Foundation Trust.

### **8.3. Study Coordinating Centre**

The trial co-ordinating centre will be at the NPEU CTU University of Oxford where the Trial Co-ordinator will be based. The NPEU CTU will be responsible for study data entry, statistical analyses, servicing both the DMC and Trial Steering Committee (TSC), and, in collaboration with the Chief Investigators and the Local Research Midwives/Nurse(s) for the general day-to-day running of the study including recruitment of sites and training of staff. An emergency helpline is available for out-of-hours queries relating to the trial.

#### **8.4. Project Management Group (PMG)**

The study will be supervised on a day-to-day basis by the Project Management Group (PMG). This group reports to the TSC.

The core PMG will ordinarily consist of the Chief Investigators and NPEU CTU staff including:

- Director – Clinical Trials Unit
- Senior Trials Manager
- Trial Coordinator
- Trial Statistician
- Administrator/Data Manager

The core PMG will meet regularly (at least monthly).

#### **8.5. Co-Investigators Group**

The Co-Investigators' Group (CIG) will meet at regular intervals throughout the duration of the trial; this will comprise all co-applicants and the members of the core PMG.

#### **8.6. Trial Steering Committee (TSC)**

The role of the TSC is to provide the overall supervision of the study. The TSC will monitor the progress of the study and conduct and advise on its scientific credibility. The TSC will consider and act, as appropriate, upon the recommendations of the DMC and ultimately carries the responsibility for deciding whether a trial needs to be stopped on grounds of safety or efficacy.

A TSC charter will be agreed at the first TSC meeting to document how the committee will operate.

#### **8.7. Data Monitoring Committee (DMC)**

A DMC independent of the applicants and the TSC will review the progress of the trial at least annually and provide advice on the conduct of the trial to the TSC. The committee will periodically review study progress and outcomes. The timings and content of the DMC reviews will be detailed in a DMC Charter, which will be agreed at its first meeting.

#### **8.8. Adjudication Panel**

A sub-group of the co-investigators and other senior clinicians will form a review panel to perform blinded outcome adjudication, as required.

## **8.9. Competing Interests**

All PHOENIX co-investigators will declare competing interests or affiliations. Members of the TSC and DMC committees and any observers to their meetings will be required to declare any competing interests they may have prior to participating in the meeting as documented within the charters.

## **9. Direct Access to Source Data and Documents**

Direct access to source data/documents (including hospital records/notes, clinical charts, laboratory reports, pharmacy records and test reports) will be granted to authorised representatives from the NPEU CTU, the Sponsor and host organisations to permit study related monitoring, audits and inspections.

## **10. Ethics and Regulatory Approvals**

### **10.1. Declaration of Helsinki**

Investigators will ensure that this study is conducted in accordance with the principles of the Declaration of Helsinki (October 2008).

### **10.2. Good Clinical Practice**

The conduct of this study will be in full compliance with the relevant regulations and Good Clinical Practice.

### **10.3. Approvals**

The study will only start after gaining approval from a NHS registered REC. Additionally, approval of the appropriate Trust R&D Office will be sought for individual trial sites.

Applications will be submitted through the Integrated Research Application System (IRAS).

A copy of the protocol, Participant Information Leaflet, Informed Consent Form, and GP Letter will be submitted to the REC for approval.

The CI or their delegate will submit and, where necessary, obtain approval from the REC and the appropriate Trust R&D Offices for any substantial amendments.

Substantial amendments are defined as those that affect:

- the safety or physical or mental integrity of the subjects of the trial
- the scientific value of the trial
- the conduct or management of the trial or
- the quality or safety of any investigational medicinal product used in the trial.

## **11. Trial Procedures**

### **11.1. Informed Consent**

Written consent will be sought from the woman only after she has been given a full verbal explanation and written description (via the participant information leaflet [PIL]) of the trial. Women who do not speak English will only be approached if an adult interpreter is available. Relatives may not interpret.

Introductory verbal and written information should be offered to all potentially eligible women with pre-eclampsia at the study's recruiting centres.

Written informed consent will be given using an informed consent form (ICF) completed, signed and dated by the woman (with countersignature by an interpreter where required) and signed by the person who obtained informed consent; this will be the Principal Investigator (PI) or another study doctor with delegated authority.

A copy of the signed ICF will be given to the woman. A further copy will be retained in the woman's medical notes, a copy will be retained in the Investigator Site File (ISF), and the original will be sent to the PHOENIX Coordinating Centre.

At all stages it will be made clear to the woman that she is free to withdraw from the trial at any time without the need to provide any reason or explanation. Participants will be made aware that this decision will have no impact on any aspect of their continuing care.

### **11.2. Data Collection**

#### **11.2.1 Data Collection before Post-natal Discharge**

Much of the outcome data for this trial are routinely recorded clinical items that can be obtained from the clinical notes or local hospital results system. No additional blood or tissue samples are required for this study. Clinical information will be collected using the following eCRFs:

- Screening Log
- Eligibility

- Maternal Details
- Prior to Randomisation
- EQ-5D-5L<sup>7</sup>
- Contact Details
- Abnormal Lab Parameters
- Delivery
- Maternal Discharge
- Maternal Outcomes
- Infant Delivery
- Infant Discharge

Women will be requested to complete the EQ-5D-5L<sup>7</sup> questionnaire at the time of randomisation: this usually takes fewer than five minutes. The data will be entered onto the trial database by the local research team.

### **11.2.2 Data Collection after Discharge**

Questionnaires will be sent to all participants at 6 months post-delivery and 2 years of age corrected for prematurity. Participants will be invited to complete the paper copy of the questionnaire and return this via FREEPOST to the Coordinating Centre, or to complete an on-line version that will be captured by the MedSciNet study database.

The 6 month questionnaire will collect the following data:

- EQ-5D-5L<sup>7</sup>
- SF-12v2®<sup>8</sup>
- Maternal Health and Social Care use from hospital discharge
- Infant Health and Social Care use from hospital discharge

The 2 year questionnaire will collect:

- EQ-5D-5L<sup>7</sup>
- SF-12v2®<sup>8</sup>
- Maternal Health and Social Care use (for the previous six months only)
- Infant Health and Social Care use (for the previous six months only)
- PARCA-R6 (Parent Report of Children's Abilities – Revised)

### **11.3. Data Processing**

All hospital trial data will be collected using bespoke eCRFs and entered directly into the study's electronic database by the centre's research staff. Data will be single entered only and at the point of entry the data will undergo a number of validation checks to verify the validity and completeness of the data captured. An additional sign-off of the maternal outcomes data will be performed by the site PI for each participant.

Follow-up questionnaires completed by the mother on-line will also undergo a number of validation checks at the point of entry. Paper copies of the questionnaire completed and returned to the Coordinating Centre will be entered manually by a member of the coordinating team.

### **11.4. Masking**

Due to the nature of this study masking of the clinicians, nursing staff, and participants is not possible.

### **11.5. End of Trial**

The PHOENIX trial has two phases: an intervention phase and a follow-up phase. The end of the intervention phase will be when the last participating mother and infant have been discharged from hospital. NHS Trusts will be notified of the end of trial for their records.

For regulatory purposes the end of the study is defined as the date when the study database is locked. An End of Study Declaration will be made to the approving Research Ethics Committee (REC) within 3 months of this date.

### **11.6. Early Cessation**

In the light of interim data and other evidence from relevant studies, the DMC will inform the TSC if, in its view, there is proof beyond reasonable doubt that the data indicate that the trial should be terminated. A decision to inform the TSC of such a finding will in part be based on statistical considerations. Appropriate proof beyond reasonable doubt cannot be specified precisely. A difference of at least 3 standard errors in the interim analysis of a major outcome may be needed to justify halting or modifying the study prematurely, for the superiority hypothesis.

## **12. Participant Confidentiality, Data Handling and Record Keeping**

Overall responsibility for ensuring that each participant's information is kept confidential will lie with the study Sponsor. All paper documents will be stored securely and kept in strict confidence in compliance with the Data Protection Act (1998). Data entered onto the eCRFs will be automatically transferred for storage in an electronic database held by MedSciNet<sup>AB</sup> on behalf of the Sponsors in which the participant will be identified only by a study specific number and their initials. The participant's name and any other identifying details will be stored in a separate database also held by MedSciNet<sup>AB</sup> on behalf of the Sponsors. The databases will only be linked by the participant's study number. This identifiable information will be collected and retained with the participant's explicit consent to enable follow-up to be undertaken. After the study has completed and the reports published, the data will be archived in a secure physical or electronic location with controlled access.

Electronic files will be stored on a file server that has restricted access. The server is in a secure location and access is restricted to a few named individuals. Access to the building in which the NPEU CTU is situated is via an electronic tag and individual rooms are kept locked when unoccupied. Authorisation to access restricted areas of the NPEU CTU network is as described in the NPEU CTU security policy. Data will be processed on a workstation by authorised staff. The computer workstations access the network via a login name and password (changed regularly). No data are stored on individual workstations. Backing up is done automatically overnight to an offsite storage area. The location of the back-up computer is in a separate department which has electronic tag access. Access to the room in which the back-up machine is located is via a key-pad system.

### **12.1. Retention of Personal Data**

Personal data will be needed to contact the participant, to thank them for participating in the study, to facilitate follow-up at 6 months and 2 years of age to co-ordinate follow up, and to disseminate the results of the study to participants.

### **12.2. Data Security**

An IT Security Risk assessment of MedsciNet AB will be undertaken by the sponsor and a data sharing agreements instigated to ensure all study data is captured and stored as per the sponsor's Security Policy and complies with all required UK data storage requirements prior to recruitment commencing.

A similar risk assessment and data sharing agreement will also be instigated to ensure EQ-5D-5L data captured via the Euroqol website is also captured, stored and transferred to the MedSciNet database as per the sponsor's security policy.

### **12.3. Insurance**

Kings College London/Guy's and St Thomas' NHS Foundation Trust, as Co-Sponsors of the study, have a specialist insurance policy in place which would operate in the event of any participant suffering harm as a result of their involvement in the research. NHS indemnity operates in respect of the clinical treatment which is provided.

## **13. Quality Control and Assurance**

### **13.1. Site Initiation and Training**

The site PI and Local Research Midwife or Nurse (LRMN), or their delegates, from each recruiting centre will be fully trained in the protocol and data collection procedures. They will then be responsible for delivering this training to all relevant site staff, to make sure that they are conversant with the trial's procedures prior to opening their centre for recruitment. The LRMN, with support from the Trial Research Midwife (TRM), will also promote the trial so that the necessary recruitment targets are reached within the timescale. The site PI and LRMN will have primary responsibility for educating any new clinicians and research staff at their centre about the trial, for maintaining enthusiasm, and encouraging recruitment in their centre. The LRMN will act as the point of contact for the PHOENIX Coordinating Centre and the TRM who will troubleshoot as the need arises.

### **13.2. Site Monitoring and Auditing**

The LRMN with support from the TRM will be responsible for the day-to-day smooth running of the trial at a recruiting site. The CTU will monitor recruitment against targets, provide staff education and training, and monitor data collection completeness and quality. The study monitor will perform regular visits to all recruiting centres and will perform source data verification on selected participants during these visits.

### **13.3. Risk Assessment**

A study risk assessment has been performed as part of the application to receive funding. This risk assessment will be reviewed at regular intervals during the course of the study and be updated as required.

### **13.4. National Registration Systems**

The study is registered on the ISRCTN register (ISRCTN01879376).

## **14. Communication**

After REC approval has been obtained, this protocol will be submitted for publication and will be available for download via the NPEU website.

### **14.1. Study Website**

The PHOENIX study website will provide information regarding the study to recruiting centres, participants and their families. Copies of all eCRFs, the study protocol, participant information leaflet and training literature will be available along with information on centres participating in the study and contact details for the Coordinating Centre. The participant's page will also provide links to other websites that may provide advice and support to people affected by pre-eclampsia.

### **14.2. Publication Policy**

The CI and NPEU CTU will coordinate dissemination of the results from this trial. All publications using data from this trial to undertake original analyses will be submitted to the TSC for review before release. The research will be published in high impact, peer reviewed, scientific journals. More general dissemination of the results will be achieved through publication of summary findings. There are no commercial or intellectual rights issues that would delay publication of results. A writing committee drawn from the co-investigators (trial grant holders), trial co-ordinators and others substantially involved in execution, analysis and interpretation will be named authors on the principal publications arising from the trial provided they meet the authorship criteria used by most high impact peer reviewed journals see <http://www.icmje.org>.

Local Principal Investigators will be named formally as collaborators on the publication; other trial personnel with significant input to the running of the trial will be named in the Acknowledgements in publications. The Chief Investigators will nominate and agree appropriate authorship on all publications prior to commencement of writing.

## **15. Finance**

### **15.1. Funding**

The study is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme. (project reference 12/25/03)

## 16. Signatures

### 16.1. Protocol Approval Signatures

The signatures below constitute approval of the PHOENIX protocol and provide assurance that this study will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to ethical and regulatory requirements, other applicable regulations and GCP.



04/10/2018

Co-Chief Investigator

Date

Professor Andrew Shennan



04/10/2018

Co-Chief Investigator

Date

Professor Lucy Chappell



04/10/2018

Statistician

Date

Louise Linsell

## 16.2. Site Principal Investigator Signatures

By signing this protocol signature page, I agree to:

- Conduct the study in accordance with the PHOENIX protocol and only make changes in order to protect the safety, rights or welfare of the participants
- Personally conduct or supervise the study and ensure that all associates, colleagues and employees assisting in the conduct of the study are informed about their obligations
- Ensure requirements with regard to obtaining informed consent are adhered
- Report unexpected SAEs that occur during the course of the study and maintain adequate and accurate records to enable representatives of the Sponsor or regulatory authority to confirm adherence with the protocol

---

Principal Investigator's Signature

---

Date

---

Print name

## 17. References

- 1 Steegers E. A, von Dadelszen P, Duvekot J. J, Pijnenborg R. Pre-eclampsia. *Lancet* 2010 Aug 21; 376(9741):631-44.
- 2 Chappell L. C, Duckworth S, Seed P. T, Griffin M, Redman C. W. G, Shennan A. H. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. *Circulation* 2013; 128(19):2121-31.
- 3 Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH; Vitamins in Pre-eclampsia (VIP) Trial Consortium. *Lancet*. 2006 Apr 8;367(9517):1145-54.
- 4 Churchill D, Duley L, Thornton J. G, Jones L. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation (Review). *Cochrane Database Syst Rev*. 2013 Jul 26;7:CD003106.
- 5 Von Dadelszen P, Payne B, Li J, Ansermino J. M, Broughton Pipkin F, Cote A. M, Douglas M. J, Gruslin A, Hutcheon J. A, Joseph K. S, Kyle P. M, Loghna P, Menzies J. M, Merialdi M, Millman A. L, Moore M. P, Moutquin J. M, Ouellet A. B, Smith G. N, Walker J. J, Walley K. R, Walters B. N, Widmer M, Lee S. K, Russel J. A, Magee L. A, PIERS Study Group. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. *Lancet*. 2011 Jan 15; 377 (9761): 219-27.
- 6 PARCA-R is a questionnaire for assessing cognitive and language development in preterm infants born at or after 32 weeks gestation, validated against a gold standard developmental assessment.
- 7 EQ-5D-5L™ is a standardised instrument for use as a measure of health outcome. It is applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. It is primarily designed for self-completion by respondents and is ideally suited for use in postal surveys, in clinics and face-to-face interviews. It is cognitively simple, taking only a few minutes to complete. Instructions to respondents are included in the questionnaire. EQ-5D-5L™ is a trade mark of the EuroQol Group.
- 8 QualityMetric's SF-12v2® Health Survey is a shorter version of the SF-36v2® Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view. Taking only two to three minutes to complete, the SF-12v2 is a

recognised as a practical, reliable, and valid measure of physical and mental health and is particularly useful in large population health surveys or for applications that combine a generic and disease-specific health survey.

- 9 Centre for Maternal and Child Enquiries (CMACE). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer: 2006–08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011;118 (Suppl. 1):1–203.
- 10 National Institute for Clinical Excellence. Process and Methods Guides. Methods of Technology Assessment 2013. 2013 Apr 4. <http://publications.nice.org.uk/pmg9>.
- 11 ONS – Gestation-Specific Infant Mortality in England and Wales, 2013 Release
- 12 National Institute for Health and Clinical Excellence. (2008) Antenatal care. <http://guidance.nice.org.uk/CG62/Guidance>.
- 13 National Institute for Health and Clinical Excellence. (2010) Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. <http://http://guidance.nice.org.uk/CG127>
- 14 Kahan B. C, Morris T. P. Reporting and analysis of trials using stratified randomisation in leading medical journals: reviews and reanalysis. BMJ. 2012; 345:e5840
- 15 Zou G. Y. A modified Poisson regression approach to prospective studies with binary data. American Journal of Epidemiology 2004; 159(7): 702-706.
- 16 The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 4 (2014) 97–104.
- 17 American College of Obstetricians and Gynaecologists. Hypertension in Pregnancy. Task Force on Hypertension in Pregnancy, American College of Obstetricians and Gynaecologists. 2013.Washington DC
- 18 National Institute for Clinical Excellence. (2013) QS35 Hypertension in Pregnancy. <http://publications.nice.org.uk/hypertension-in-pregnancy-qs35>.

## Appendix 1: PEACOCK (PHOENIX-2) Study



### Prognostic indicators of severe disEAsE in women with late preterm pre-eClampsia tO guide deCision maKing on timing of delivery

ISRCTN01879376

#### Sponsor:

Name: King's College London and Guy's and St Thomas' NHS Foundation Trust  
Address: Strand  
London  
WC2R 2LS  
Telephone: 020 7836 5454

#### Chief Investigator

Name: Professor Lucy Chappell  
Address: Women's Health Academic Centre  
Division of Women's Health  
10<sup>th</sup> Floor North Wing  
St. Thomas' Hospital  
London  
SE1 7EH  
Telephone: 020 7188 3639  
Email: [lucy.chappell@kcl.ac.uk](mailto:lucy.chappell@kcl.ac.uk)

#### Name and address of Statistician

Name: Louise Linsell  
Address: NPEU, Clinical Trials Unit  
University of Oxford  
Old Road Campus  
Oxford  
OX3 7LF  
Telephone: 01865 617922  
Email: [louise.linsell@npeu.ox.ac.uk](mailto:louise.linsell@npeu.ox.ac.uk)

## CONTENTS

<b>1</b>	<b>Synopsis</b>	<b>44</b>
<b>2</b>	<b>Abbreviations</b>	<b>45</b>
<b>3</b>	<b>Background &amp; Rationale</b>	<b>45</b>
<b>4</b>	<b>Study Objectives, Design and Statistics</b>	<b>46</b>
4.1	Study Objectives	46
4.2	Study Design	46
4.3	Sample size	46
4.4	Statistical Analysis	47
<b>5</b>	<b>Selection and Withdrawal of Participants</b>	<b>47</b>
5.1	Inclusion and Exclusion Criteria	47
5.2	Study Periods	47
<b>6</b>	<b>Assessment of Outcomes</b>	<b>47</b>
6.1	Primary Outcome	47
6.2	Secondary Outcomes	47
6.3	Study Procedures (for Assessing Outcomes)	48
<b>7</b>	<b>Study Governance</b>	<b>48</b>
<b>8</b>	<b>Ethics and Regulatory Approvals</b>	<b>48</b>
8.1	Approvals	48
<b>9</b>	<b>Study Procedures</b>	<b>48</b>
9.1	Informed Consent	48
9.2	Intervention – Blood Sample Collection	49
9.3	Blood Sample Analysis	49
9.4	Safety Reporting	49
9.5	Data Processing & Storage	49
<b>10</b>	<b>Finance</b>	<b>50</b>
<b>11</b>	<b>References</b>	<b>50</b>
<b>12</b>	<b>Signatures</b>	<b>51</b>
12.1	Protocol Approval Signatures	51
12.2	Site Principal Investigator Signatures	52

# 1 Synopsis

<b>Title of Study</b>	Prognostic indicators of severe disEAsE in women with late preterm pre-eClampsia tO guide deCision maKIng on timing of delivery
<b>Protocol Acronym</b>	PEACOCK (PHOENIX-2) study
<b>Sponsor Name</b>	King's College London
<b>Chief Investigator</b>	Professor Lucy Chappell
<b>REC number</b>	13/SC/0645
<b>Medical Condition or Disease Under Investigation</b>	Women with late preterm pre-eclampsia (34 <sup>+0</sup> to 36 <sup>+6</sup> weeks gestation)
<b>Purpose of Study</b>	To validate a prognostic model to inform optimal timing of delivery in women with late preterm pre-eclampsia, and to compare prognostic and incremental value of novel candidate biomarkers (e.g. plasma placental growth factor (PIGF)), with clinical and routinely collected blood/urinary markers to determine clinically indicated need for delivery within seven days of assessment.
<b>Primary Objective</b>	The primary objective of the study is: <ul style="list-style-type: none"> <li>To validate and optimise a prognostic model in women with late preterm pre-eclampsia to determine clinically indicated need for delivery within seven days of assessment</li> </ul>
<b>Secondary Objective(s)</b>	The secondary objectives of the study are: <ul style="list-style-type: none"> <li>To develop and optimise a prognostic model in women with late preterm pre-eclampsia to determine clinically indicated need for delivery within 48 hours and within 14 days of assessment</li> <li>To evaluate the prognostic model for prediction of perinatal deaths within seven days of delivery or neonatal unit (NNU) admissions.</li> </ul>
<b>Study Design</b>	Prospective observational cohort study nested within the main PHOENIX study, measuring candidate biomarkers in women with late preterm pre-eclampsia. The test result will not be revealed to the clinical team. The study will be conducted in selected centres participating in the main PHOENIX study across England and Wales.

<b>Outcomes</b>	<p><b>Primary outcome:</b></p> <p>Primary short-term maternal outcome: Clinically indicated need for delivery for pre-eclampsia (or related complications) within seven days of assessment.</p> <p><b>Secondary outcomes:</b></p> <ul style="list-style-type: none"> <li>• Clinically indicated need for delivery for pre-eclampsia within 48 hours and within 14 days of assessment.</li> <li>• Perinatal death</li> <li>• NNU admission</li> </ul>
<b>Sample Size</b>	500 women with pre-eclampsia between 34 <sup>+0</sup> and 36 <sup>+6</sup> weeks of gestation, eligible for the PHOENIX study.
<b>Summary of eligibility criteria</b>	<p><b>Inclusion criteria:</b> As for the main PHOENIX study plus written informed consent to the PEACOCK study.</p> <p><b>Exclusion criterion:</b> As for the main PHOENIX study.</p> <p>Women who are <b>eligible</b> for the main PHOENIX study are eligible to participate in the PEACOCK (PHOENIX-2) nested study, whether they agree or decline randomisation into the main PHOENIX study.</p>
<b>Interventions</b>	Non-revealed blood test for biomarker measurement at enrolment.

## 2 Abbreviations

<b>PIGF</b>	Placental Growth Factor
<b>PREP</b>	Prediction of Risk of Early Onset Pre-eclampsia

## 3 Background & Rationale

Current risk assessment of women with pre-eclampsia is based on clinical history, observation of clinical signs, and non-specific biomarkers (such as full blood counts, kidney and liver function tests and clotting function). Current evidence suggests that clinical signs or symptoms may be mediated in part by an imbalance of circulating angiogenic factors of placental origin. The PEACOCK (PHOENIX-2) study will compare the novel candidate biomarkers (e.g. PIGF),<sup>1</sup> with clinical data and routinely collected blood/urinary parameters<sup>2</sup> in isolation and combination to determine clinically indicated need for delivery for pre-eclampsia (or related complications)

within seven days of assessment. Predictors to be collected include routinely collected clinical data, blood and urinary parameters included in the final PREP (Prediction of Risk of Early Onset Pre-eclampsia) model.<sup>2</sup> Test performance will be evaluated for the predictors individually and in combination. Development of a prognostic model based on clinical data and blood/urinary markers in women with preterm preeclampsia may improve the ability of clinicians to determine who is at greatest risk of need for delivery, enabling timely intervention, whilst the babies of women at lower risk may benefit from prolongation of gestation.

## 4 Study Objectives, Design and Statistics

### 4.1 Study Objectives

The aim of this study is to validate a prognostic model to inform optimal timing of delivery in women with late preterm pre-eclampsia, and to compare prognostic and incremental value of novel candidate biomarkers (e.g. PIGF), with clinical data and routinely collected blood/urinary markers to determine clinically indicated need for delivery within seven days of assessment.

The primary objective of the study is:

- To validate and optimise a prognostic model in women with late preterm pre-eclampsia to determine clinically indicated need for delivery within seven days of assessment.

The secondary objectives of the study are:

- To develop and optimise a prognostic model in women with late preterm pre-eclampsia to determine clinically indicated need for delivery within 48 hours and within 14 days of assessment
- To evaluate the prognostic model for prediction of perinatal deaths within seven days of delivery or neonatal unit (NNU) admissions

### 4.2 Study Design

PEACOCK (PHOENIX-2) is a prospective observational cohort study nested within the main PHOENIX study, measuring novel candidate biomarkers (e.g. PIGF) in women with late preterm pre-eclampsia. The study will be conducted in selected centres participating in the main PHOENIX study across England and Wales.

### 4.3 Sample size

A minimum of 100 women with informative outcomes would be required to validate the existing model,<sup>3</sup> evaluate a new biomarker and assess extension of existing predictive model with the

new biomarker.<sup>4</sup> We estimate that the primary outcome will occur in 40% of cases with expectant management, based on our previous work<sup>1</sup> and other literature. This would require a sample size of 500 women in total.

#### 4.4 Statistical Analysis

The performance of the clinical factors model and PIGF alone will be evaluated for discrimination and calibration in the validation sample of women enrolled into PEACOCK. Discrimination will be assessed using the C-statistic and calibration will be quantified using the calibration slope and the expected/observed statistic. The incremental value of adding PIGF to the clinical model will be determined using net reclassification improvement.<sup>5</sup>

## 5 Selection and Withdrawal of Participants

### 5.1 Inclusion and Exclusion Criteria

The inclusion and exclusion criteria for recruitment for the PEACOCK (PHOENIX-2) nested study are the same as for the main PHOENIX study plus written informed consent to the PEACOCK study. Women who are **eligible** for the main PHOENIX study are eligible to participate in the PEACOCK (PHOENIX-2) nested study, whether they agree or decline randomisation into the main PHOENIX study.

### 5.2 Study Periods

A woman's participation in the study may be from 34 weeks gestation until delivery and discharge from hospital of the mother and baby. For regulatory purposes the end of the study will be the same as the end of the main PHOENIX study as the study's database cannot be locked until this time.

## 6 Assessment of Outcomes

### 6.1 Primary Outcome

- Clinically indicated need for delivery for pre-eclampsia (or related complications) within seven days of assessment

### 6.2 Secondary Outcomes

- Clinically indicated need for delivery for pre-eclampsia within 48 hours and within 14 days of assessment.
- Perinatal death
- NNU admission

### 6.3 Study Procedures (for Assessing Outcomes)

The study procedures from randomisation until hospital discharge of mother and baby are identical to the main PHOENIX study (apart from the EQ-5D-5L questionnaire that is not required for PEACOCK (PHOENIX-2)), with the addition of non-revealed blood tests for PIGF measurement at the time of enrolment and subsequently thereafter if routine bloods are taken for clinical care, up until the time of delivery.

## 7 Study Governance

The PEACOCK (PHOENIX-2) study will be supervised by the same PMG/TSC/DMC as the main PHOENIX study, with additional individual input from the PEACOCK (PHOENIX-2) CIG. The CIG includes the PEACOCK (PHOENIX-2) co-applicants and the PMG.

## 8 Ethics and Regulatory Approvals

### 8.1 Approvals

PEACOCK (PHOENIX-2) is a nested study under the main PHOENIX study and as such is included within the main study ethics approval. The updated protocol, Participant Information Leaflet and Informed Consent Form are a substantial amendment to the main study. The nested study will only start once these amendments have been approved by the REC. Additionally, approval of the appropriate Trust R&D Office will be sought for all PEACOCK study sites.

## 9 Study Procedures

### 9.1 Informed Consent

Only when eligible women have agreed or declined to participate in the main PHOENIX study will they receive a full verbal explanation and written description of the PEACOCK (PHOENIX-2) study. Women who do not speak English will only be approached if an adult interpreter is available. Relatives may not interpret.

Written informed consent will be taken using an informed consent form (ICF) completed, signed and dated by the woman (with countersignature by an interpreter where required) and signed by the person who obtained informed consent; this will be the Principal Investigator (PI) or another healthcare professional with delegated authority.

A copy of the signed Informed Consent Form will be given to the woman. A further copy will be retained in the woman's medical notes, a copy will be retained in the ISF, and the original will be sent to the Coordinating Centre.

At all stages it will be made clear to the woman that she is free to withdraw from the PEACOCK (PHOENIX-2) study at any time without the need to provide an explanation. Participants will be made aware that this decision will have no impact on any aspect of their continuing care.

## **9.2 Intervention – Blood Sample Collection**

The intervention for the PEACOCK (PHOENIX-2) study is a non-revealed blood sample for biomarker (e.g. PIGF) measurement taken after written informed consent has been given. Additional non-revealed blood samples, for biomarker measurement, may be taken at the same time as clinically indicated blood samples up until the time of delivery and as described in the PEACOCK section of the PHOENIX handbook.

## **9.3 Blood Sample Analysis**

The PEACOCK blood samples will be tested in either:

- the Sponsor hospital laboratory at St Thomas' Hospital or
- the local hospital laboratory or research laboratory (only where a masked reading can be provided)

The readings will not be revealed to the clinical team and therefore the biomarker measurements do not have to be performed immediately after sampling. Sample disposal will comply with all legal and regulatory requirements from the Human Tissue Act (2004), and any amendments thereto. The results of the blood samples will not be revealed to the clinicians, nursing staff or participants.

## **9.4 Safety Reporting**

Safety reporting for PEACOCK (PHOENIX-2) will be identical to the main PHOENIX study (see sections 7.5).

## **9.5 Data Processing & Storage**

All hospital study data for PEACOCK (PHOENIX-2) will be recorded as detailed in section 11.2.1 for PHOENIX-1 with the exception of EQ-5D. The data will be stored on the main PHOENIX database (see section 11.2.1-3).

## 10 Finance

The PEACOCK (PHOENIX-2) study is funded by NIHR HTA Monitoring Add on Studies programme (project reference 15/59/06).


## 11 References

1. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. *Circulation* 2013;128(19):2121-31 doi: 10.1161/CIRCULATIONAHA.113.003215.
2. Thangaratnam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, Ganzevoort W, Akkermans J, Kerry S, Mol BW, Moons KG, Riley RD, Khan KS; PREP Collaborative Network. Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. *BMC Med*. 2017;15(1):68. doi: 10.1186/s12916-017-0827-3.
3. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. *Stat Med*. 2016 Jan 30;35(2):214-26. doi: 10.1002/sim.6787.
4. Nieboer D, Vergouwe Y, Ankerst DP, Roobol MJ, Steyerberg EW. Improving prediction models with new markers: a comparison of updating strategies. *BMC Med Res Methodol*. 2016 Sep 27;16(1):128.
5. Pencina MJ1, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med*. 2008 Jan 30;27(2):157-72.

## 12 Signatures

### 12.1 Protocol Approval Signatures

The signatures below constitute approval of the PEACOCK study protocol and provide assurance that this study will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to ethical and regulatory requirements, other applicable regulations and GCP.




04/10/2018

Chief Investigator

Date

Professor Lucy Chappell



04/10/2018

Statistician

Date

Louise Linsell

## 12.2 Site Principal Investigator Signatures

By signing this PEACOCK study protocol signature page, I agree to:

- Conduct the study in accordance with the protocol and only make changes in order to protect the safety, rights or welfare of the participants
- Personally conduct or supervise the study and ensure that all associates, colleagues and employees assisting in the conduct of the study are informed about their obligations
- Ensure requirements with regard to obtaining informed consent are adhered
- Report unexpected SAEs that occur during the course of the study and maintain adequate and accurate records to enable representatives of the Sponsor or regulatory authority to confirm adherence with the protocol

\_\_\_\_\_  
Principal Investigator's Signature

\_\_\_\_\_  
Date

\_\_\_\_\_  
Print name

**Appendix 2 - PHOEBE (PHOENIX-3) study**



**Mechanisms of action of intervention in the PHOENIX trial: in women with preterm pre-eclampsia; does planned delivery improve postpartum maternal cardiac function through attenuation of myocardial ischaemia at time of disease?**

ISRCTN01879376

**Sponsor:**

Name: King's College London and Guy's and St Thomas' NHS Foundation Trust  
Address: Strand  
London  
WC2R 2LS  
Telephone: 020 7836 5454

**Chief Investigators**

Name: Dr Fergus McCarthy/Professor Lucy Chappell  
Address: Women's Health Academic Centre  
Division of Women's Health  
10<sup>th</sup> Floor North Wing  
St. Thomas' Hospital  
London  
SE1 7EH  
Telephone: 020 7188 3639  
Email: [fergus.mccarthy@kcl.ac.uk](mailto:fergus.mccarthy@kcl.ac.uk) / [lucy.chappell@kcl.ac.uk](mailto:lucy.chappell@kcl.ac.uk)

**Name and address of Statistician**

Name: Louise Linsell  
Address: NPEU, Clinical Trials Unit  
University of Oxford  
Old Road Campus  
Oxford  
OX3 7LF  
Telephone: 01865 617922  
Email: [louise.linsell@npeu.ox.ac.uk](mailto:louise.linsell@npeu.ox.ac.uk)

## CONTENTS

<b>1</b>	<b>Synopsis</b>	<b>55</b>
<b>2</b>	<b>Abbreviations</b>	<b>56</b>
<b>3</b>	<b>Background and Rationale</b>	<b>57</b>
<b>4</b>	<b>Study Objectives, Design and Statistics</b>	<b>57</b>
4.1	Study Objectives	57
4.2	Study Design	58
4.3	Sample Size	58
4.4	Statistical analysis	58
<b>5</b>	<b>Selection and Withdrawal of Participants</b>	<b>58</b>
5.1	Inclusion and Exclusion Criteria	58
5.2	Study Periods	58
<b>6</b>	<b>Assessment of Outcomes</b>	<b>59</b>
6.1	Primary Outcome	59
6.2	Secondary Outcomes	59
6.3	Study Procedures (for Assessing Outcomes)	59
<b>7</b>	<b>Study Governance</b>	<b>59</b>
<b>8</b>	<b>Ethics and Regulatory Approvals</b>	<b>59</b>
8.1	Approvals	59
<b>9</b>	<b>Study Procedures</b>	<b>60</b>
9.1	Informed Consent	60
9.2	Interventions	60
9.3	Blood Sample Collection	61
9.4	Blood Sample Analysis	61
9.5	Data Collection after Discharge	61
9.6	Echocardiogram	61
9.7	Safety Reporting	61
9.8	Data Processing & Storage	61
<b>10</b>	<b>Finance</b>	<b>62</b>
<b>11</b>	<b>References</b>	<b>62</b>
<b>12</b>	<b>Signatures</b>	<b>63</b>
12.1	Protocol Approval Signatures	63
12.2	Site Principal Investigator Signatures	64

# 1 Synopsis

<b>Title of Study</b>	Mechanisms of action of intervention in the PHOENIX trial: in women with preterm pre-eclampsia; does planned delivery improve postpartum maternal cardiac function through attenuation of myocardial ischaemia at time of disease?
<b>Protocol Acronym</b>	PHOEBE (PHOENIX-3)
<b>Sponsor Name</b>	King's College London
<b>Chief Investigators</b>	Dr Fergus McCarthy/Professor Lucy Chappell
<b>REC number</b>	13/SC/0645
<b>Medical Condition or Disease Under Investigation</b>	Long-term cardiovascular function in women with late preterm pre-eclampsia (34 <sup>+0</sup> to 36 <sup>+6</sup> weeks gestation)
<b>Purpose of Study</b>	To examine the effects of delivery in women with late preterm pre-eclampsia, compared to expectant management and delivery at 37 weeks gestation on cardiovascular function at six months postpartum.
<b>Primary Objective</b>	The primary long term objective of the study: <ul style="list-style-type: none"> <li>To investigate whether delivery in women with late preterm pre-eclampsia compared to expectant management, may attenuate adverse maternal cardiovascular function, by examining diastolic and systolic function at six months postpartum.</li> </ul>
<b>Secondary Objective(s)</b>	The secondary objectives of the study are: <ul style="list-style-type: none"> <li>To evaluate whether diastolic blood pressure, systolic blood pressure, heart rate or the cardiovascular components of the fullPIERS composite outcome differs in women managed by planned immediate delivery compared with those managed expectantly.</li> <li>To evaluate whether differences in postpartum maternal cardiovascular function in women managed by planned delivery compared to expectant management are related to measurements of cardiac ischaemia (e.g. highly sensitive cardiac Troponin I and Cardiac Myosin Binding Protein C).</li> </ul>

<b>Study Design</b>	Prospective observational study nested within the main PHOENIX study, measuring markers of cardiac ischaemia in women with late preterm pre-eclampsia, and measuring diastolic/systolic cardiac function six months postpartum after a pre-eclamptic pregnancy. The blood test result will not be revealed to the clinical team. The study will be conducted in selected centres participating in the main PHOENIX study across England and Wales.
<b>Outcomes</b>	<p><b>Primary outcome:</b></p> <p>Primary long-term maternal outcome:</p> <p>Composite of diastolic and systolic function classified according to the American College of Cardiology (see the PHOEBE section within the PHOENIX study handbook) as assessed by echocardiography with tissue Doppler studies at six months postpartum.</p> <p><b>Secondary outcomes:</b></p> <p>Secondary maternal outcomes:</p> <p>Diastolic blood pressure systolic blood pressure, heart rate and cardiovascular components of the fullPIERS composite outcome (between enrolment and maternal discharge).</p>
<b>Sample Size</b>	322 women with pre-eclampsia between 34 <sup>+0</sup> and 36 <sup>+6</sup> weeks of gestation eligible for the PHOENIX study (requiring 404 women recruited).
<b>Summary of eligibility criteria</b>	<p><b>Inclusion criteria:</b> As for the main PHOENIX study.</p> <p><b>Exclusion criterion:</b> As for the main PHOENIX study.</p> <p>Women who are <b>eligible</b> for the main PHOENIX study are eligible to participate in the PHOEBE (PHOENIX-3) nested study, whether they agree or decline randomisation into the main PHOENIX study.</p>
<b>Interventions</b>	Non-revealed blood test for biomarker assessment of myocardial ischaemia (e.g. for highly sensitive cardiac troponin and Cardiac Myosin Binding Protein C), together with repeat non-revealed blood test and echocardiography with tissue Doppler studies at around six months postpartum.

## 2 Abbreviations

<b>CMyC</b>	Cardiac Myosin Binding Protein C
<b>cTnl</b>	Highly sensitive cardiac troponin

### 3 Background and Rationale

The PHOEBE (PHOENIX-3) study is a prospective mechanistic study with the aim of examining the effects of prolongation of a pregnancy complicated by pre-eclampsia on cardiovascular function at six months postpartum by studying women recruited to a randomised controlled study of delivery with minimal delay versus expectant management in women with pre-eclampsia between 34<sup>+0</sup> and 36<sup>+6</sup> weeks gestation.

This is an important research question as epidemiological evidence describes an association between pregnancies complicated by pre-eclampsia and long term adverse cardiovascular function, long term morbidity and mortality including hypertension, myocardial infarction (13-fold increase), major cardiovascular events (13-fold increase), heart failure (8-fold increase), stroke (14-fold increase) and death (6-fold increase).

### 4 Study Objectives, Design and Statistics

#### 4.1 Study Objectives

The aim of this study is to examine the effects of delivery in women with late preterm pre-eclampsia, compared to expectant management and delivery at 37 weeks gestation on cardiovascular function at six months postpartum.

The primary objective of the study is:

- To investigate whether delivery in women with late preterm pre-eclampsia compared to expectant management, may attenuate adverse maternal cardiovascular function, by examining diastolic and systolic function at six months postpartum.

The secondary objectives of the study are:

- To evaluate whether diastolic blood pressure, systolic blood pressure, heart rate or the cardiovascular components of the fullPIERS composite outcome differs in women managed by planned immediate delivery compared with those managed expectantly.
- To evaluate whether differences in postpartum maternal cardiovascular function in women managed by planned delivery compared to expectant management are related to measurements of cardiac ischaemia (e.g. highly sensitive cardiac Troponin I and Cardiac Myosin Binding Protein C).

## 4.2 Study Design

PHOEBE (PHOENIX-3) is a prospective observational study nested within the main PHOENIX study, measuring markers of cardiac ischaemia in women with late preterm pre-eclampsia, and measuring diastolic/systolic cardiac function six months postpartum after a pre-eclamptic pregnancy. The study will be conducted in centres participating in the main PHOENIX study across England and Wales.

## 4.3 Sample Size

We aim to detect a 25% relative risk (from 70% to 52.5%) in the primary outcome defined as evidence of diastolic and systolic dysfunction in the planned delivery group compared with those managed expectantly<sup>1,2,3</sup>. To have a 90% chance of detecting this at the 5% significance level, complete data on 322 women (161 per groups) are needed. We will approach and enrol at least 404 women with the expectation that at least 80% will return for the echocardiogram at six months.

## 4.4 Statistical analysis

Risk ratios will be estimated for binary outcomes. For continuous measures, log transformations will be used as appropriate, and multiple regression, adjusting for key baseline predictors used to estimate the effect of the treatment.

# 5 Selection and Withdrawal of Participants

## 5.1 Inclusion and Exclusion Criteria

The inclusion and exclusion criteria for recruitment for the PHOEBE (PHOENIX-3) nested study are the same as for the main PHOENIX study. Women who are **eligible** for the main PHOENIX study are eligible to participate in the PHOEBE (PHOENIX-3) nested study, whether they agree or decline randomisation into the main PHOENIX study.

## 5.2 Study Periods

A woman's participation in the study may be from 34 weeks gestation until the echocardiogram taken at six months postpartum. For regulatory purposes the end of the study will be the same as the end of the main PHOENIX study as the database cannot be locked until this time.

## 6 Assessment of Outcomes

### 6.1 Primary Outcome

- A composite of diastolic and systolic function classified according to the American College of Cardiology (see the PHOEBE section within the PHOENIX study handbook) as assessed by echocardiography with tissue Doppler studies at six months postpartum.

### 6.2 Secondary Outcomes

- Diastolic blood pressure systolic blood pressure, heart rate and cardiovascular components of the fullPIERS composite outcome (between enrolment and maternal discharge).

### 6.3 Study Procedures (for Assessing Outcomes)

The study procedures from randomisation until discharge are identical as in the main PHOENIX study (apart from the EQ-5D questionnaire that is not required for PHOEBE (PHOENIX-3)), with additional non-revealed blood sampling for assessment of cardiac ischaemia at the time of enrolment after written informed consent is given. If feasible, further samples will be taken subsequently if routine bloods are taken for clinical care, immediately following delivery and at six months postpartum. An additional echocardiography with tissue Doppler studies will be performed on the woman at six months postpartum.

## 7 Study Governance

The PHOEBE (PHOENIX-3) study will be supervised by the same PMG/TSC/DMC as the main PHOENIX study, with additional individual management input from the PHOEBE (PHOENIX-3) CIG at regular intervals. The CIG includes the PHOEBE (PHOENIX-3) co-applicants and the PMG.

## 8 Ethics and Regulatory Approvals

### 8.1 Approvals

PHOEBE (PHOENIX-3) is a nested study under the main PHOENIX study and as such is included within the main study ethics approvals. The updated protocol, Participant Information Leaflet and Informed Consent Form are a substantial amendment to the main study. The nested study will only

start once these amendments have been approved by the REC. Additionally, approval of the appropriate Trust R&D Office will be sought for all PHOEBE (PHOENIX-3) study sites.

## 9 Study Procedures

### 9.1 Informed Consent

Only when eligible women have agreed or declined to participate in the main PHOENIX study will they receive a full verbal explanation and written description of the PHOEBE (PHOENIX-3) study. Women who do not speak English will only be approached if an adult interpreter is available. Relatives may not interpret.

Written informed consent will be taken using an informed consent form (ICF) completed, signed and dated by the woman (with countersignature by an interpreter where required) and signed by the person who obtained informed consent; this will be the Principal Investigator (PI) or another healthcare professional with delegated authority.

A copy of the signed Informed Consent Form will be given to the woman. A further copy will be retained in the woman's medical notes, a copy will be retained in the ISF, and the original will be sent to the Coordinating Centre.

At all stages it will be made clear to the woman that she is free to withdraw from the study at any time without the need to provide any reason or explanation. Participants will be made aware that this decision will have no impact on any aspect of their continuing care.

### 9.2 Interventions

The interventions for the PHOEBE (PHOENIX-3) study are:

- Non-revealed blood sampling for the assessment of cardiac ischaemia, after informed consent has been taken for the PHOEBE (PHOENIX-3) study
- If feasible, non-revealed blood sampling for the assessment of cardiac ischaemia thereafter if routine bloods are taken for clinical care, immediately following delivery and at six months postpartum
- An additional echocardiography with tissue Doppler studies will be performed on the woman at six months postpartum.

### **9.3 Blood Sample Collection**

Blood samples will be taken by the local research team, as described in the PHOEBE section of the PHOENIX study handbook, where possible at the same time as blood for routine clinical care. Blood sampling may be repeated at the same time as clinically indicated blood samples. The results of the blood samples will not be available to the clinicians, nursing staff or participants.

### **9.4 Blood Sample Analysis**

The anonymised samples will be transported to a research sampling archive for King's College London for storage prior to analysis, which may occur outside of King's College London. The results will be included in the study analysis. Sample disposal will comply with all legal and regulatory requirements from the Human Tissue Act (2004) and any amendments thereto.

### **9.5 Data Collection after Discharge**

All participants will be invited to have an echocardiogram and an additional blood test at the six month follow-up visit. This blood sample will be processed as described in section 19.8.4.

### **9.6 Echocardiogram**

An echocardiographer will perform a functional assessment of the heart six months postpartum. Results will not be shared with the woman as the long term implications or effects of intervention are unknown. When an incidental finding of a cardiac structural problem is detected on the echocardiogram, or when significant functional findings are found, these will be communicated to a cardiologist (either within the research group or a local named site cardiologist where appropriate) who will make an appropriate recommendation for further action.

### **9.7 Safety Reporting**

Safety reporting for PHOEBE (PHOENIX-3) will be identical to the main PHOENIX study (see sections 7.5)

### **9.8 Data Processing & Storage**

All hospital study data for PHOEBE (PHOENIX-3) will be recorded as detailed in section 11.2.1 for PHOENIX-1 with the exception of EQ-5D. The data will be stored on the main PHOENIX database (see section 11.2.1-3). Echocardiograph images will be stored for off-line analysis and transferred digitally for review. The process will include a quality assurance period (first six months of study), where the acquisition of echocardiography images is optimised, and quality control involving 10% of echocardiograms being over-read by a second individual (echocardiography technician) for consistency, and a further random sample being reviewed by a senior cardiologist.

## 10 Finance

The study is funded by NIHR Efficacy and Mechanism Evaluation Programme (project reference 15/23/02).


## 11 References

1. Melchiorre, K., et al., Severe myocardial impairment and chamber dysfunction in preterm preeclampsia. *Hypertens Pregnancy*, 2012. 31(4):454-71.
2. Melchiorre, K., et al., Preeclampsia is associated with persistent postpartum cardiovascular impairment. *Hypertension*, 2011. 58(4):709-15.
3. Melchiorre, K., et al., Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. *Hypertension*, 2011. 57(1):85-93.

## 12 Signatures

### 12.1 Protocol Approval Signatures

The signatures below constitute approval of the PHOEBE study protocol and provide assurance that this study will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to ethical and regulatory requirements, other applicable regulations and GCP.

  
\_\_\_\_\_ 04/10/2018  
\_\_\_\_\_


Co-Chief Investigator  
Dr Fergus McCarthy

Date

  
\_\_\_\_\_ 04/10/2018  
\_\_\_\_\_

Co-Chief Investigator  
Professor Lucy Chappell

Date

  
\_\_\_\_\_ 04/10/2018  
\_\_\_\_\_

Statistician  
Louise Linsell

Date

## 12.2 Site Principal Investigator Signatures

By signing this PHOEBE study protocol signature page, I agree to:

- Conduct the study in accordance with the protocol and only make changes in order to protect the safety, rights or welfare of the participants
- Personally conduct or supervise the study and ensure that all associates, colleagues and employees assisting in the conduct of the study are informed about their obligations
- Ensure requirements with regard to obtaining informed consent are adhered
- Report unexpected SAEs that occur during the course of the study and maintain adequate and accurate records to enable representatives of the Sponsor or regulatory authority to confirm adherence with the protocol.

\_\_\_\_\_  
Principal Investigator's Signature

\_\_\_\_\_  
Date

\_\_\_\_\_  
Print name

### **APPENDIX 3 - Study Procedures for each study**

#### Key to study procedures

1. Screening to be conducted of all women suspected of being eligible for the study.
2. Women only to be invited to participate in the PEACOCK and/or PHOEBE study after they have decided whether or not they wish to take part in the main PHOENIX Study.
3. Delivery to be commenced within 48 hours of randomisation for women participating in PHOENIX randomised to the planned delivery group.
4. Eligibility for study to be assessed from blood pressure recorded at the time the diagnosis of pre-eclampsia.
5. Blood systolic pressure reading within the 48 hours prior to randomisation to be recorded.
6. Highest systolic blood pressure recorded between randomisation and delivery to be recorded.
7. Highest systolic blood pressure recorded between delivery and discharge to be recorded.
8. Haematology and/or Biochemistry results that contributed to diagnosis of pre-eclampsia to be recorded.
9. The most recent Haematology and/or Biochemistry results prior to randomisation to be recorded.
10. Abnormal Haematology and/or Biochemistry results from randomisation to discharge to be recorded at discharge.
11. Research blood samples to be taken at the time of consent with additional samples to be taken at the time of routine bloods when possible up until the time of delivery.
12. Research blood samples to be taken, if possible, within 24 hours post-delivery and at the six month follow-up visit.
13. Serious Adverse Events (SAEs) to be recorded from randomisation to post-natal discharge. Only unexpected SAEs to be reported.
14. Brief details of anti-hypertensive and medication for induction will be recorded; all other concomitant medication will only be recorded in the event that an unexpected SAE is reported.
15. EQ-5D-5L<sup>7</sup> to be given to the participant to complete immediately after randomisation.

## Study Procedures

Procedure	Screening <sup>1</sup>	Randomisation	Delivery <sup>2</sup>	Post-natal Hospital Discharge	6 Months Following Birth	Infant 2 Years of Age Corrected for Prematurity
Obstetric Medical History	● ● ●					
Consent <sup>3</sup>	● ● ●					
Demography	● ● ●					
Blood Pressure	● ● ● <sup>4</sup>	● ● ● <sup>5</sup>	● ● ● <sup>6</sup>	● ● ● <sup>7</sup>	● <sup>12</sup>	
Haematology and Biochemistry	● ● ● <sup>8</sup>	● ● ● <sup>9</sup>		● ● ● <sup>10</sup>		
Research Blood Samples		● ● ● <sup>11</sup>	● ● <sup>11</sup>	● <sup>12</sup>	● <sup>12</sup>	
Reason for Delivery			● ● ●			
Mode of Delivery			● ● ●			
Birth weight			● ● ●			
Umbilical Venous and Arterial pH			● ● ●			
APGAR Assessment			● ● ●			
SAEs <sup>13</sup>		● ● ●	● ● ●	● ● ●		
Concomitant Medication <sup>14</sup>	● ● ●	● ● ●	● ● ●	● ● ●		
PARCA-R Assessment						●
EQ-5D-5L Questionnaire <sup>15</sup>		●			●	●
SF-12 v2 <sup>®</sup> Questionnaire					●	●
Echocardiogram					●	

● PHOENIX ● PEACOCK ● PHOEBE (footnotes are on facing page)



## Contact Details

PHOENIX Coordinating Centre

NPEU Clinical Trials Unit  
Nuffield Department of Population Health  
University of Oxford  
Old Road Campus  
Oxford  
OX3 7LF

Telephone: 01865 289 733

Fax: 01865 289 740

Email: [phoenix@npeu.ox.ac.uk](mailto:phoenix@npeu.ox.ac.uk)

[www.npeu.ox.ac.uk/phoenix](http://www.npeu.ox.ac.uk/phoenix)



The PHOENIX and PEACOCK studies are funded by the National Institute for Health Research's HTA Programme (project references 12/25/03 & 15/59/06) and the PHOEBE study is funded by the National Institute for Health Research's EME Programme (project reference 15/23/02).

Guy's and St Thomas'   
NHS Foundation Trust

